AMEX:PLX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Protalix BioTherapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PLX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

18.7%

PLX

-0.9%

US Biotechs

2.5%

US Market


1 Year Return

-4.1%

PLX

24.5%

US Biotechs

8.4%

US Market

Return vs Industry: PLX underperformed the US Biotechs industry which returned 23.4% over the past year.

Return vs Market: PLX underperformed the US Market which returned 7.1% over the past year.


Shareholder returns

PLXIndustryMarket
7 Day18.7%-0.9%2.5%
30 Day-20.8%3.2%5.1%
90 Day7.6%13.6%2.0%
1 Year-4.1%-4.1%25.7%24.5%10.9%8.4%
3 Year-61.5%-61.5%32.2%27.8%30.5%21.9%
5 Year-83.6%-83.6%-3.4%-9.2%56.9%39.2%

Price Volatility Vs. Market

How volatile is Protalix BioTherapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Protalix BioTherapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Protalix BioTherapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalix BioTherapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Protalix BioTherapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

30.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PLX's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if PLX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PLX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PLX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PLX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Protalix BioTherapeutics performed over the past 5 years?

2.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PLX is currently unprofitable.

Growing Profit Margin: PLX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PLX is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.

Accelerating Growth: Unable to compare PLX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PLX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: PLX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Protalix BioTherapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PLX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PLX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PLX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PLX has sufficient cash runway for 11 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: PLX is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Protalix BioTherapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PLX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PLX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PLX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PLX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PLX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.8yrs

Average management tenure


CEO

Dror Bashan (52yo)

0.92

Tenure

US$566,324

Compensation

Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019, Mr. Bashan has over 20 years of experience in the pharmaceutical industry wit ...


CEO Compensation Analysis

Compensation vs Market: Dror's total compensation ($USD566.32K) is about average for companies of similar size in the US market ($USD589.04K).

Compensation vs Earnings: Insufficient data to compare Dror's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Dror Bashan
President0.92yrUS$566.32kno data
Yoseph Shaaltiel
Founder and Executive VP Research & Development13.42yrsUS$468.32k0.25% $282.5k
Eyal Rubin
Senior VP0.67yrUS$369.10kno data
Yaron Naos
Senior Vice President of Operations2yrsUS$385.74k0.062% $70.8k
Einat Brill-Almon
Senior Vice President of Product Development13.42yrsUS$422.18k0.057% $65.7k
Dafna Shelly
Vice President of Human Resources9.5yrsno datano data

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: PLX's management team is seasoned and experienced (5.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dror Bashan
President0.92yrUS$566.32kno data
Amos Shalev
Independent Director11.83yrsUS$80.00k0.00052% $598.9
Aaron Schwartz
Independent Director5.5yrsUS$80.00k0.20% $227.2k
Gwen Melincoff
Director0.33yrno datano data
Charles Arntzen
Member of Scientific Advisory Board3.92yrsno datano data
David Granot
Independent Director1.75yrsUS$80.00kno data
Alexander Levitzki
Member of Scientific Advisory Boardno datano datano data
J. Ciechanover
Member of Scientific Advisory Board12.75yrsno datano data
Zeev Bronfeld
Independent Chairman0.75yrUS$80.00k0.67% $767.7k
Roger Kornberg
Chairman of Scientific Advisory Boardno dataUS$55.00kno data

2.8yrs

Average Tenure

72yo

Average Age

Experienced Board: PLX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PLX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118.6%.


Top Shareholders

Company Information

Protalix BioTherapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Protalix BioTherapeutics, Inc.
  • Ticker: PLX
  • Exchange: AMEX
  • Founded: 1993
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$115.171m
  • Shares outstanding: 32.44m
  • Website: https://www.protalix.com

Number of Employees


Location

  • Protalix BioTherapeutics, Inc.
  • 2 Snunit Street
  • Science Park
  • Karmiel
  • 2161401
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PLXAMEX (NYSE MKT LLC)YesOrdinary SharesUSUSDJan 2007
PBDADB (Deutsche Boerse AG)YesOrdinary SharesDEEURJan 2007
PLXTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSJan 2007

Biography

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/29 02:18
End of Day Share Price2020/05/28 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.